Cryofocus Medtech (Shanghai) Co. Ltd. Class H
HHKEX:69222.39
HKD
+0.04
(+1.70%)
Cryofocus Medtech (Shanghai) Co. Ltd. Class H
HKEX:6922
(Hong Kong Exchange)
Recent
price
2.39
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Semi-annual Revenue
CNY
•
in mil. unless spec.Semi-annual Earnings Per Share
CNY
•
in mil. unless spec.Semi-annual Dividends Per Share
CNY
•
in mil. unless spec.- Similar Companies
- Business
- Cryofocus Medtech (Shanghai) Co., Ltd. engages in the development, manufacture, and sale of minimally invasive interventional cryotherapy medical devices and related products. The company focuses on two primary therapeutic areas: vascular interventional therapy for cardiovascular conditions such as atrial fibrillation and hypertension, and natural orifice transluminal endoscopic surgery for diseases of the urinary, respiratory, and digestive tracts. Core product categories include cryoablation systems and disposable cryoprobes for interventional procedures; ancillary and consumable devices such as endoscopic clips, laparoscopic biopsy bags, ureteral dilation catheters, and related laparoscopic instruments; and non-cryotherapy devices such as anti-reflux systems. Cryofocus develops products that span diagnostic and therapeutic interventional platforms, with a portfolio that also includes specialized tools for bladder, lung, and gastrointestinal interventions, as well as wounding retractors and single-port multi-channel access platforms. The company operates primarily in the People’s Republic of China, with ongoing efforts to expand internationally, and maintains its headquarters in Shanghai. Cryofocus was founded in 2013 and is listed on the Hong Kong Stock Exchange under ticker 6922.HK. The group emphasizes a dual-engine model of research and commercialization, aiming to accelerate clinical development, broaden its minimally invasive interventional cryotherapy portfolio, and selectively scale global operations while continuing to strengthen its core technology platforms and intellectual property position. Substantive subsidiaries and corporate relationships position Cryofocus as a centralized platform for cryoablation-based medical devices, with strategic partnerships and collaborations advancing regulatory approvals, clinical trials, and commercialization milestones across multiple markets. Recent strategic moves include intensified clinical development, expansion of the respiratory and oncology intervention segments, and targeted global expansion to broaden market reach, alongside ongoing regulatory submissions and product registrations in key jurisdictions. The company’s market-facing communications emphasize its role as a global platform for minimally invasive interventional cryotherapy, with ongoing investments in pipeline advancement and ecosystem collaborations to push commercialization of its core AF Cryoablation System and related therapeutic solutions.